Rationale: The goal was to connect elements of idiopathic pulmonary fibrosis (IPF) pathogenesis, including chronic endoplasmic reticulum stress in respiratory epithelia associated with injury/inflammation and remodeling, distal airway mucus obstruction and honeycomb cyst formation with accumulation of MUC5B (mucin 5B), and associations between IPF risk and polymorphisms in the MUC5B promoter. Objectives: To test whether the endoplasmic reticulum (ER) stress sensor protein ERN2 (ER-to-nucleus signaling 2) and its downstream effector, the spliced form of XBP1S (X-box-binding protein 1), regulate MUC5B expression and differentially activate the MUC5B promoter variant in respiratory epithelia. Methods: Primary human airway epithelial (HAE) cells, transgenic mouse models, human IPF lung tissues, and cell lines expressing XBP1S and MUC5B promoters were used to explore relationships between the ERN2/XBP1S pathway and MUC5B. An inhibitor of the pathway, KIRA6, and XBP1 CRISPR-Cas9 were used in HAE cells to explore therapeutic potential. Measurements and Main Results: ERN2 regulated MUC5B and MUC5AC mRNAs. Downstream XBP1S selectively promoted MUC5B expression in vitro and in distal murine airway epithelia in vivo. XBP1S bound to the proximal region of the MUC5B promoter and differentially upregulated MUC5B expression in the context of the MUC5B promoter rs35705950 variant. High levels of ERN2 and XBP1S were associated with excessive MUC5B mRNAs in distal airways of human IPF lungs. Cytokine-induced MUC5B expression in HAE cells was inhibited by KIRA6 and XBP1 CRISPR-Cas9. Conclusions: A positive feedback bistable ERN2-XBP1S pathway regulates MUC5B-dominated mucus obstruction in IPF, providing an unfolded protein response-dependent mechanism linking the MUC5B promoter rs35705950 polymorphism with IPF pathogenesis. Inhibiting ERN2-dependent pathways/elements may provide a therapeutic option for IPF.
Rationale: The goal was to connect elements of idiopathic pulmonary fibrosis (IPF) pathogenesis, including chronic endoplasmic reticulum stress in respiratory epithelia associated with injury/inflammation and remodeling, distal airway mucus obstruction and honeycomb cyst formation with accumulation of MUC5B (mucin 5B), and associations between IPF risk and polymorphisms in the MUC5B promoter. Objectives: To test whether the endoplasmic reticulum (ER) stress sensor protein ERN2 (ER-to-nucleus signaling 2) and its downstream effector, the spliced form of XBP1S (X-box-binding protein 1), regulate MUC5B expression and differentially activate the MUC5B promoter variant in respiratory epithelia. Methods: Primary human airway epithelial (HAE) cells, transgenic mouse models, human IPF lung tissues, and cell lines expressing XBP1S and MUC5B promoters were used to explore relationships between the ERN2/XBP1S pathway and MUC5B. An inhibitor of the pathway, KIRA6, and XBP1 CRISPR-Cas9 were used in HAE cells to explore therapeutic potential. Measurements and Main Results:ERN2 regulated MUC5B and MUC5AC mRNAs. Downstream XBP1S selectively promoted MUC5B expression in vitro and in distal murine airway epithelia in vivo. XBP1S bound to the proximal region of the MUC5B promoter and differentially upregulated MUC5B expression in the context of the MUC5B promoter rs35705950 variant. High levels of ERN2 and XBP1S were associated with excessive MUC5B mRNAs in distal airways of human IPF lungs. Cytokine-induced MUC5B expression in HAE cells was inhibited by KIRA6 and XBP1 CRISPR-Cas9. Conclusions: A positive feedback bistable ERN2-XBP1S pathway regulates MUC5B-dominated mucus obstruction in IPF, providing an unfolded protein response-dependent mechanism linking the MUC5B promoter rs35705950 polymorphism with IPF pathogenesis. Inhibiting ERN2-dependent pathways/elements may provide a therapeutic option for IPF.
Authors: Dan Han; Alana G Lerner; Lieselotte Vande Walle; John-Paul Upton; Weihong Xu; Andrew Hagen; Bradley J Backes; Scott A Oakes; Feroz R Papa Journal: Cell Date: 2009-08-07 Impact factor: 41.582
Authors: Mark S Wilson; Satish K Madala; Thirumalai R Ramalingam; Bernadette R Gochuico; Ivan O Rosas; Allen W Cheever; Thomas A Wynn Journal: J Exp Med Date: 2010-02-22 Impact factor: 14.307
Authors: Sung-Woo Park; Catherine Verhaeghe; Louis T Nguyenvu; Rebecca Barbeau; Christopher J Eisley; Yasuhiro Nakagami; Xiaozhu Huang; Prescott G Woodruff; John V Fahy; David J Erle Journal: Am J Respir Crit Care Med Date: 2009-07-23 Impact factor: 21.405
Authors: Rajarshi Ghosh; Likun Wang; Eric S Wang; B Gayani K Perera; Aeid Igbaria; Shuhei Morita; Kris Prado; Maike Thamsen; Deborah Caswell; Hector Macias; Kurt F Weiberth; Micah J Gliedt; Marcel V Alavi; Sanjay B Hari; Arinjay K Mitra; Barun Bhhatarai; Stephan C Schürer; Erik L Snapp; Douglas B Gould; Michael S German; Bradley J Backes; Dustin J Maly; Scott A Oakes; Feroz R Papa Journal: Cell Date: 2014-07-10 Impact factor: 41.582
Authors: Martina Korfei; Clemens Ruppert; Poornima Mahavadi; Ingrid Henneke; Philipp Markart; Miriam Koch; Gyoergy Lang; Ludger Fink; Rainer-Maria Bohle; Werner Seeger; Timothy E Weaver; Andreas Guenther Journal: Am J Respir Crit Care Med Date: 2008-07-17 Impact factor: 21.405
Authors: Arthur Kaser; Ann-Hwee Lee; Andre Franke; Jonathan N Glickman; Sebastian Zeissig; Herbert Tilg; Edward E S Nieuwenhuis; Darren E Higgins; Stefan Schreiber; Laurie H Glimcher; Richard S Blumberg Journal: Cell Date: 2008-09-05 Impact factor: 41.582
Authors: Wanda K O'Neal; Richard C Boucher; Alessandra Livraghi-Butrico; Barbara R Grubb; Kristen J Wilkinson; Allison S Volmer; Kimberly A Burns; Christopher M Evans Journal: Mucosal Immunol Date: 2016-07-20 Impact factor: 7.313
Authors: Minzhe Guo; Koichi Tomoshige; Michael Meister; Thomas Muley; Takuya Fukazawa; Tomoshi Tsuchiya; Rebekah Karns; Arne Warth; Iris M Fink-Baldauf; Takeshi Nagayasu; Yoshio Naomoto; Yan Xu; Marcus A Mall; Yutaka Maeda Journal: EMBO Mol Med Date: 2017-04 Impact factor: 12.137
Authors: Sydney B Montesi; Jolene H Fisher; Fernando J Martinez; Moisés Selman; Annie Pardo; Kerri A Johannson Journal: Am J Respir Crit Care Med Date: 2020-08-15 Impact factor: 21.405
Authors: Paolo Spagnolo; Jonathan A Kropski; Mark G Jones; Joyce S Lee; Giulio Rossi; Theodoros Karampitsakos; Toby M Maher; Argyrios Tzouvelekis; Christopher J Ryerson Journal: Pharmacol Ther Date: 2020-12-24 Impact factor: 13.400
Authors: Gang Chen; Ling Sun; Takafumi Kato; Kenichi Okuda; Mary B Martino; Aiman Abzhanova; Jennifer M Lin; Rodney C Gilmore; Bethany D Batson; Yvonne K O'Neal; Allison S Volmer; Hong Dang; Yangmei Deng; Scott H Randell; Brian Button; Alessandra Livraghi-Butrico; Mehmet Kesimer; Carla Mp Ribeiro; Wanda K O'Neal; Richard C Boucher Journal: J Clin Invest Date: 2019-10-01 Impact factor: 19.456
Authors: Cameron B Morrison; Kendall M Shaffer; Kenza C Araba; Matthew R Markovetz; Jason A Wykoff; Nancy L Quinney; Shuyu Hao; Martial F Delion; Alexis L Flen; Lisa C Morton; Jimmy Liao; David B Hill; Mitchell L Drumm; Wanda K O'Neal; Mehmet Kesimer; Martina Gentzsch; Camille Ehre Journal: Eur Respir J Date: 2022-02-03 Impact factor: 16.671